The Oral Revolution in Psoriasis & Melasma: Current Evidence and Emerging Pipelines

Abstract

Psoriasis and melasma are chronic dermatological conditions posing significant therapeutic challenges due to their complex pathophysiology and variable clinical presentation. Recent advancements have led to the emergence of orally administered therapies, revolutionizing the management landscape for both disorders. This review evaluates the current evidence surrounding oral treatments, elucidates their mechanisms of action, and examines the ongoing development of novel oral agents. By synthesizing research from recent clinical trials and guideline updates, this article aims to provide healthcare professionals with an up-to-date, practical, and evidence-based overview for optimizing patient outcomes in psoriasis and melasma.

Introduction

Psoriasis and melasma represent two distinct yet prevalent dermatological disorders that substantially impact patient quality of life. While psoriasis is a chronic immune-mediated inflammatory disease characterized by erythematous, scaly plaques, melasma is a pigmentary disorder marked by hyperpigmented macules, commonly on sun-exposed areas of the face. Historically, topical and phototherapeutic modalities have dominated the treatment algorithms for both conditions, but their limitations—including incomplete efficacy and adherence challenges—have spurred the development of oral therapeutics. Recent research highlights the promise of oral small molecules, immunomodulators, and antioxidants, offering new hope in disease control. This review explores the epidemiology, pathogenesis, clinical features, diagnostic strategies, and evolving oral treatment landscape for both psoriasis and melasma, providing insights for evidence-based clinical decision-making.

Epidemiology / Disease Burden

Psoriasis affects approximately 2-3% of the global population, with higher incidence in Western countries. The disease onset can occur at any age but commonly presents in early adulthood. Psoriasis is associated with significant comorbidities, including psoriatic arthritis, metabolic syndrome, cardiovascular disease, and psychological distress, emphasizing its systemic nature. Melasma predominantly affects women of reproductive age, with the highest prevalence in Fitzpatrick skin types III-V and in populations residing in regions with high ultraviolet exposure. Though not life-threatening, melasma leads to substantial psychosocial morbidity. Both conditions exhibit chronicity and relapse, underscoring the need for durable, patient-friendly therapeutic strategies.

Pathophysiology

Psoriasis pathogenesis involves a complex interplay between genetic susceptibility, immune dysregulation, and environmental triggers. Central to its pathophysiology is the aberrant activation of T-helper 17 (Th17) cells, leading to overproduction of pro-inflammatory cytokines such as IL-17, IL-23, and TNF-α, which drive keratinocyte hyperproliferation and altered skin barrier function. Melasma, in contrast, is primarily a disorder of hyperactive melanogenesis. Ultraviolet radiation, hormonal influences, and genetic factors upregulate melanocyte activity via pathways involving melanocortin-1 receptor (MC1R) and Wnt/β-catenin signaling. Recent studies highlight the role of oxidative stress, vascular factors, and subclinical inflammation in melasma, suggesting overlaps in the pathogenic mechanisms of pigmentary and inflammatory skin diseases.

Risk Factors

Psoriasis risk factors include genetic predisposition (notably HLA-Cw6), obesity, smoking, alcohol consumption, certain medications (e.g., lithium, beta-blockers), infections, and psychological stress. Melasma risk is heightened by female sex, pregnancy, oral contraceptive use, family history, phototoxic drugs, and chronic sun exposure. Both disorders are exacerbated by environmental factors, immune dysregulation, and hormonal changes, pointing to the multifactorial nature of disease onset and progression.

Clinical Features

Psoriasis manifests as well-demarcated, erythematous plaques with silvery scale, commonly involving the extensor surfaces, scalp, and sacral region. Subtypes include plaque, guttate, pustular, inverse, and erythrodermic psoriasis. Pruritus, nail changes, and arthropathy may occur. Melasma presents as symmetrical, irregularly bordered, hyperpigmented macules and patches, often on the cheeks, forehead, upper lip, and chin. Patterns include centrofacial, malar, and mandibular. Both conditions can cause significant cosmetic and psychosocial distress, influencing treatment priorities and adherence.

Diagnosis

Diagnosis of psoriasis is primarily clinical, supported by characteristic morphology and distribution. Skin biopsy may be warranted in atypical cases. Severity is assessed using tools such as the Psoriasis Area and Severity Index (PASI) and Body Surface Area (BSA). Melasma is diagnosed based on clinical evaluation and history, with Wood\'s lamp examination aiding in differentiating epidermal and dermal pigmentation. Dermoscopy and, rarely, histopathology may assist in ambiguous cases. Assessment of disease impact and identification of triggers are essential components of the diagnostic workup.

Treatment & Management

Traditional psoriasis management includes topical corticosteroids, vitamin D analogs, phototherapy, and systemic agents such as methotrexate, cyclosporine, and acitretin. Biologic therapies targeting TNF-α, IL-17, and IL-23 have transformed moderate-to-severe disease management but entail high costs and parenteral administration. Melasma treatment focuses on photoprotection, topical depigmenting agents (hydroquinone, azelaic acid, retinoids), and procedural interventions (chemical peels, lasers). However, recurrence and incomplete response remain common, necessitating the exploration of oral therapies.

Recent Advances / Emerging Therapies

The advent of oral small molecules and systemic antioxidants marks a paradigm shift in the management of both psoriasis and melasma. In psoriasis, oral phosphodiesterase-4 (PDE4) inhibitors (e.g., apremilast) and Janus kinase (JAK) inhibitors (e.g., deucravacitinib) offer effective, non-biologic oral options with favorable safety profiles. Apremilast has demonstrated efficacy in plaque psoriasis and psoriatic arthritis, with manageable adverse events such as gastrointestinal upset and mood changes. Deucravacitinib, a selective TYK2 inhibitor, has shown promising results in phase 3 trials, offering a novel mechanism targeting the IL-23/IL-17 axis.
melasma, oral tranexamic acid (TXA) has garnered considerable attention, demonstrating significant pigment reduction in randomized trials, likely via inhibition of plasminogen activation and subsequent melanocyte suppression. Oral antioxidants—including polypodium leucotomos extract, glutathione, and proanthocyanidins—have shown adjunctive efficacy by mitigating oxidative stress and inflammation. The safety profile of these agents is under active investigation, with TXA-associated thromboembolic risk being a key consideration.
Emerging pipelines include oral melanogenesis inhibitors, tyrosinase antagonists, and agents modulating the skin\'s microbiome, broadening future therapeutic horizons for both conditions.

Guideline Recommendations

Recent guidelines endorse oral PDE4 inhibitors and TYK2 inhibitors as alternatives for patients with moderate-to-severe psoriasis who are intolerant or inadequately responsive to conventional systemic or biologic therapies. Comprehensive assessment of comorbidities and individualized risk-benefit analysis are emphasized. For melasma, expert consensus supports the adjunctive use of oral TXA in refractory cases, with strict exclusion of individuals at risk for thromboembolism. Oral antioxidants may be considered as supportive therapies, but robust long-term data are pending. Multimodal approaches—combining oral, topical, and procedural interventions—are recommended for optimal results.

Conclusion

The oral revolution in psoriasis and melasma management reflects a growing understanding of disease mechanisms and the need for patient-centric, effective, and convenient therapies. Oral small molecules, immunomodulators, and antioxidants are expanding therapeutic options, offering new hope for individuals with recalcitrant or extensive disease. Ongoing research and pipeline developments are poised to further refine oral treatment strategies, promising enhanced efficacy, safety, and quality of life for patients. Clinicians must remain up-to-date with evolving evidence and guideline recommendations to tailor therapy, minimize risks, and optimize outcomes in these chronic dermatological disorders.